Latest Health News

Nutritional Growth Solutions (ASX – NGS) has locked in a $2 million capital raise through a share placement aimed at fueling sales, inventory, and growth initiatives, pending shareholder approval.

LCL Resources Limited faces suspension from ASX trading due to failure to lodge a required periodic report on time, raising questions about the company’s compliance and operational transparency.

West African Resources Limited reported a robust quarterly cash flow with strong operating inflows and substantial cash reserves, underscoring its solid financial footing amid ongoing exploration investments.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Westpac Banking Corporation reported a solid $6.9 billion statutory net profit for 2025, maintaining strong capital and credit quality while increasing dividends. The bank’s ongoing transformation and disciplined growth underpin its outlook amid evolving economic conditions.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Infinity Mining Limited reported a net cash outflow of A$143,000 for the September quarter, with cash reserves dwindling to A$30,000. The company is pursuing cost-saving measures and an imminent capital raising to secure its short-term future.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Cyclone Metals advances its flagship Iron Bear Project despite a minor delay in drilling caused by First Nations election disputes, while strengthening its cash position through significant share sales.

DGR Global Limited’s Q3 2025 report reveals ongoing project development, strategic equity holdings, and complex legal proceedings shaping its resource company creation model.